Isabella Ciccone, MPH

The CEO and cofounder at Advanced Brain Monitoring talked about how exploring electroencephalography patterns can help differentiate between Alzheimer disease, Lewy body dementia, and frontotemporal dementia. [WATCH TIME: 3 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of July 2024, compiled all into one place by the NeurologyLive® team.

A duo of experts highlighted the need for further studies on the exploration of how exposure to wildfire particulate matter impacts neurodegenerative diseases. [WATCH TIME: 2 minutes]

The director of the Brain Health Observatory at the University of Southern California discussed how blood tests for Alzheimer disease could significantly reduce diagnostic wait times and improve treatment monitoring. [WATCH TIME: 4 minutes]

Treatment of the first randomized patient with preclinical Alzheimer disease in the phase 2b ReTain trial assessing JNJ-2056 is anticipated in the third quarter of 2024.

The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS stressed how new clinical trial designs for cervical dystonia should incorporate more flexible and patient-centered approaches, including new measurement scales and the use of technology. [WATCH TIME: 5 minutes]

The president at Fasikl and the Laverne and Joyce Rider professor of neurology at the University of Kansas Medical Center talked about results from a pilot study assessing the Felix Neural AI wristband in patients with essential tremor. [WATCH TIME: 4 minutes]

Using plasma p-tau217 shows promise as an effective, less invasive pre-screening method for identifying amyloid-β positive individuals in Alzheimer disease clinical trials.

The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS talked about a recent study that examined the varying methods and results of clinical trials assessing the duration and efficacy of botulinum toxin treatment in cervical dystonia. [WATCH TIME: 7 minutes]

The use of a blood test significantly improved diagnostic accuracy compared with standard clinical evaluations for Alzheimer disease, especially in primary and secondary care settings.

The vice president of scientific engagement at Alzheimer's Association talked about recent studies that highlight the progress made in blood biomarker tests for diagnosis, the impact of air pollution on brain health, and promising treatments for Alzheimer disease. [WATCH TIME: 8 minutes]

A study recently presented at AAIC 2024 showed that higher consumption of processed red meat significantly increased the risk of dementia and cognitive decline among adults in the United States.

The director of the Brain Health Observatory at the University of Southern California discussed the potential impact of Alzheimer disease blood tests on reducing clinic wait times and improving the diagnostic process in primary care.

The assistant professor at Duke University School of Nursing talked about a project aimed at developing a music-based mobile app to improve sleep for individuals with dementia and their caregivers. [WATCH TIME: 5 minutes]

The professor of neuroscience at Imperial College London talked about results from a study assessing a glucagon-like peptide-1 analogue, liraglutide, in patients with Alzheimer disease. [WATCH TIME: 5 minutes]

A duo of experts talked about the association of long-term exposure to fine particulate matter from wildfires and the increased risk of dementia among older adults. [WATCH TIME: 7 minutes]

The director of the Brain Health Observatory at the University of Southern California talked about integrating blood tests into primary care to better triage patients with Alzheimer disease, reduce unnecessary referrals, and shorten appointment wait times. [WATCH TIME: 7 minutes]

The application was supported by positive data of KYV-101 in patients with stiff-person syndrome treated in Germany under a named-patient treatment option.

Michael Soileau, MD, FAAN, talked about a panel of specialists who discussed the evolution and multidisciplinary treatment of Parkinson disease, emphasizing patient-centered care and advanced therapeutic options.

Tiziana Life Sciences’ intranasal foralumab has shown potential in treating nonactive secondary progressive multiple sclerosis through innovative immune modulation.

Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.

Pending positive results from an early-stage trial, a mid-stage study evaluating MyoPAXon’s effect on other targeted muscles and muscle function will be initiated.

The director of movement disorders at the Banner Sun Health Research Institute talked about recent, promising advancements for diagnosing atypical Parkinsonian disorders and the questions that remain.

The professor of neurology at Stony Brook Medicine talked about the promising potential in ongoing studies assessing BTK inhibitors as treatment for primary progressive multiple sclerosis. [WATCH TIME: 3 minutes]

The assistant professor at Hunter College talked about the approach of localization to prevent misdiagnoses of multiple sclerosis and ensure patients receive appropriate treatment. [WATCH TIME: 3 minutes]

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.

The neuroradiologist at Mayo Clinic discussed the categorization of biomarkers for Alzheimer disease, focusing on core biomarkers specific to the disease and those reflecting related pathologies. [WATCH TIME: 8 minutes]

A recent study showed significant retinal damage in patients with double-antibody seronegative neuromyelitis optica spectrum disorders following optic neuritis.

A duo of experts from Mayo Clinic discussed how recent developments in clinical criteria for diagnosing limbic-predominant amnestic neurodegenerative syndrome allow for more accurate differentiation from Alzheimer disease. [WATCH TIME: 9 minutes]

Lomecel-B is made from living cells called medicinal signaling cells that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45.